Movement Alert｜Halozyme Therapeutics Rises 5.38% in Pre-Market Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Sharply Raised

Market Focus08-07

On August 7, Halozyme Therapeutics rose 5.38% in pre-market trading, trading at $90.9 per share, with turnover of $2,634.59.

The move was driven by the company's Q2 earnings release, which delivered a comprehensive beat across all key metrics. Q2 adjusted EPS came in at $2.28, surpassing the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, beating the consensus estimate of approximately $402 million by roughly 19%, up 47.7% year-over-year.

Simultaneously, the company significantly raised its full-year guidance, now expecting adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, up from prior guidance of $7.75 to $8.25 EPS on revenue of $1.71 billion to $1.81 billion. Both metrics substantially exceed FactSet consensus estimates of $7.94 EPS and $1.77 billion in revenue. The outperformance was primarily driven by continued strong royalty growth from its ENHANZE drug delivery technology platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109283581?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109283581","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Halozyme Therapeutics Rises 5.38% in Pre-Market Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Sharply Raised","media":"Market Focus","content":"<p><p>On August 7, Halozyme Therapeutics rose 5.38% in pre-market trading, trading at $90.9 per share, with turnover of $2,634.59.</p><p>The move was driven by the company's Q2 earnings release, which delivered a comprehensive beat across all key metrics. Q2 adjusted EPS came in at $2.28, surpassing the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, beating the consensus estimate of approximately $402 million by roughly 19%, up 47.7% year-over-year.</p><p>Simultaneously, the company significantly raised its full-year guidance, now expecting adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, up from prior guidance of $7.75 to $8.25 EPS on revenue of $1.71 billion to $1.81 billion. Both metrics substantially exceed FactSet consensus estimates of $7.94 EPS and $1.77 billion in revenue. The outperformance was primarily driven by continued strong royalty growth from its ENHANZE drug delivery technology platform.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Halozyme Therapeutics Rises 5.38% in Pre-Market Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Sharply Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Halozyme Therapeutics Rises 5.38% in Pre-Market Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Sharply Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 16:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Halozyme Therapeutics rose 5.38% in pre-market trading, trading at $90.9 per share, with turnover of $2,634.59.</p><p>The move was driven by the company's Q2 earnings release, which delivered a comprehensive beat across all key metrics. Q2 adjusted EPS came in at $2.28, surpassing the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, beating the consensus estimate of approximately $402 million by roughly 19%, up 47.7% year-over-year.</p><p>Simultaneously, the company significantly raised its full-year guidance, now expecting adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, up from prior guidance of $7.75 to $8.25 EPS on revenue of $1.71 billion to $1.81 billion. Both metrics substantially exceed FactSet consensus estimates of $7.94 EPS and $1.77 billion in revenue. The outperformance was primarily driven by continued strong royalty growth from its ENHANZE drug delivery technology platform.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"","article_id":"1109283581","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109283581","pubTimestamp":1786091585,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Halozyme Therapeutics rose 5.38% in pre-market trading, trading at $90.9 per share, with turnover of $2,634.59.The move was driven by the company's Q2 earnings release, which delivered a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"走势提醒|Halozyme Therapeutics 盘前交易上涨 5.38%，第二季度盈利大幅超出预期，全年指引大幅上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"On August 7, Halozyme Therapeutics rose 5.38% in pre-market trading, trading at $90.9 per share, with turnover of $2,634.59.The move was driven by the company's Q2 earnings release, which delivered a comprehensive beat across all key metrics. Q2 adjusted EPS came in at $2.28, surpassing the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, beating the consensus estimate of approximately $402 million by roughly 19%, up 47.7% year-over-year.Simultaneously, the company significantly raised its full-year guidance, now expecting adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, up from prior guidance of $7.75 to $8.25 EPS on revenue of $1.71 billion to $1.81 billion. Both metrics substantially exceed FactSet consensus estimates of $7.94 EPS and $1.77 billion in revenue. The outperformance was primarily driven by continued strong royalty growth from its ENHANZE drug delivery technology platform.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109283581","isCrawlerRequest":true}